

Anti-URO-1 (J143) Antibody, Paramagnetic


Model # R2122

WAVESENSE

Intended Use:

For In Vitro Diagnostic Use.

This product is intended for selective recovery/enrichment of cells expressing the URO-1 cell surface antigen in biological fluids and tissue culture.



Description:

Anti-Uro-1 (J143) Antibody, Paramagnetic are submicron, uniform diameter, paramagnetic particles conjugated with mouse monoclonal J143 antibody. The J143 antibody was developed using the 253J bladder cancer cell line. The J143 antibody recognizes the alpha 3 subunit of VLA-3 (ECMR I - extracellular matrix receptor I, URO-1). The antibody detects 3 components of the alpha 3 subunit glycoprotein complex (MW 30kDa, 120kDa and 140kDa). VLA proteins are part of the integrin family of cell adhesion molecules.

Supplied As:

Catalog #	Contains
R2122-1	1 mL

1mg of Anti-URO-1 (J143) conjugated paramagnetic particles in 1 mL of 0.02 M Phosphate Buffer pH 7.4, 0.15 M NaCl, 1.0% BSA, 0.09% Sodium Azide.

Storage:

This product is stable when stored at 4 – 8°C. DO NOT FREEZE. DO NOT STORE AT ROOM TEMPERATURE. Refer to product label for expiration date.

Other Information:

Resuspend particles prior to each use by inversion or gentle pulse vortexing several times. Avoid causing foam when resuspending particles. Generally, 25 µL to 100 µL of antibody will be sufficient to capture cells in specimen volumes up to 5 mL.

Material Safety Data:

When handling this material Standard Laboratory Practices should be followed. This material's chemical, physical and toxicological properties have not been thoroughly investigated. Contains Sodium Azide as a preservative. Although, the quantity of Sodium Azide (0.09%) is very small, measures should be taken to avoid skin and eye contact, inhalation and ingestion. Sodium Azide (NaN₃) may react with lead and copper plumbing to form potentially explosive metal oxides. Upon disposal, flush with a large volume of water to prevent azide build-up.

References:

1. Fradet, Y., et al. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. USA 81: 224-228, 1984.
2. Hemler, M., et al. Multiple very late antigen (VLA) heterodimers on platelets. J. Biol. Chem. 263: 7660-7665, 1988.
3. Leibert, M., et al. Expression of the VLA beta 1 integrin family in bladder cancer. Am. J. Path. 144: 1016-1022, 1994.



15339 Barranca Pkwy
Irvine, CA 92618 USA
www.WaveSense.net

Toll Free: 800.807.7760
Phone: 949.341.1980
Fax: 949.341.1982
Contact@WaveSense.net

ML080422-11
© 01/31/12